Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV

AIDS

Volumn 19, Issue SUPPL. 3, 2005, Pages

  Perry, William ^a   Carlson, Meghan D ^a   Barakat, Fatma ^a   Hilsabeck, Robin C ^a,b   Schiehser, Dawn M ^a   Mathews, Christopher ^a   Hassanein, Tarek I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Co infection; Cognition; Fibrosis; Hepatitis C virus; HIV; Neuropsychological testing

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; ATTENTION; BODY BURDEN; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SAMPLE; SCREENING; VELOCITY;

EID: 27944503899     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000192074.18691.31     Document Type: Article

References (32)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
2. World Health Organization in collaboration with the Viral Hepatitis Prevention Board. Global surveillance and control of hepatitis C. J Viral Hepat 1999; 6:35-47.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
4. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-782.
5. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
6. Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM, Hayes PC. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 1998; 10:485-489.
7. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 33:433-439.
8. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 33:440-446.
9. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9:847-854.
10. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1995; 1:231-251.
11. Stout JC, Salmon DP, Butters N, Taylor M, Peavy G, Heindel WC, et al. Decline in working memory associated with HIV infection. Psychol Med 1995; 25:1221-1232.
12. Marcotte TD, Grant I, Atkinson JH, Heaton RK. Neurobehavioral complications of HIV infection. In: Medical neuropsychology. Edited by Butters M, Beers SR. New York: Kluwer Academic/Plenum Publishers; 2001. pp. 85-105.
13. Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 1991; 41:778-785.
14. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-721.
15. Hilsabeck RC, Hickman S, Boland B, Williams B, Boyd C, Hassanein TI, et al. The pattern of memory deficits in patients with end stage liver disease. J Int Neuropsychol Soc 2001; 7:169.
16. McCrea M, Cordoba J, Vesset G, Blei AT, Randolph C. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996; 53:758-763.
17. Martin EM, Novak RM, Fendrich M, Vassileva J, Gonzalez R, Grbesic S, et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc 2004; 10:298-300.
18. Von Giesen HJ, Heintges T, Abasi-Boroudjeni N, Kucukkoylu S, Koller H, Haslinger BA, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 2004; 35:131-137.
19. Ryan EL, Morgello S, Isaacs K, Phil M, Naseer M, Gerits P, et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62:957-962.
20. The French METAVIR Cooperative Study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
21. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Tuscon: Neuropsychology Press; 1993.
22. Smith A. Symbol Digit Modalities Test (SDMT): manual (revised). Los Angeles: Western Psychological Services; 1982.
23. Wechsler D. Wechsler Adult Intelligence Scale - third revision. San Antonio: The Psychological Corporation; 1997.
24. Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan battery. Odessa, FL: Psychological Assessment Resources, Inc.; 1991.
25. Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS-III/ WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc 2001; 7:867-874.
26. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, et al., and the HNRC Group. The HNRC 500 - neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1995; 1:231-251.
27. Starace R, Baldassarre C, Biancolilli B, Fea M, Serpelloni G, Bartoli L, Maj M. Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998; 97:132-138.
28. Moss HB, Tarter RE, Yao JK, Van Thiel DH. Subclinical hepatic encephalopathy: relationship between neuropsychological deficits and standard laboratory tests assessing hepatic status. Arch Clin Neuropsychol 1992; 7:419-429.
29. Trzepacz PT, Tarter RE, Shah A, Tringali R, Faett DG, Van Thiel DH. SPECT scan and cognitive findings in subclinical hepatic encephalopathy. J Neuropsychiatry Clin Neurosci 1994; 6:170-175.
30. Fernandez I, Rubio R, Lumbreras C. Hepatitis C in HIV-infected patients - therapeutic approach. Clin Microbiol Infect 2002; 8:80-84.
31. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, Kucukkoylu S, Koller H, Haslinger BA, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 2004; 35:131-137.
32. Arendt G, von Giesen HJ, Hefter H, Theisen A. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. AIDS 2001; 15:493-500.